Digital biomarkers (dBM) initiatives

By collecting and analyzing patient data using wearable devices, Chugai will create new health indicators and provide new value to patients.

What are digital biomarkers (dBM)?

Digital biomarkers are indexes that objectively visualizes the presence or absence of a disease and changes caused by treatment using data obtained from smartphones and wearable devices. Digital technology is expected to acquire and analyze data that cannot be obtained from conventional biomarkers*, so we can utilize them for daily medical practice as well as for drug research and development.

Biomarkers*: Laboratory data such as vital signs, biochemical/blood test results, tumor markers, and diagnostic imaging data such as MRI and CT. They are used for both the diagnosis of diseases and predictions for treatment.

Chugai’s dBM initiatives

Chugai leverages wearable devices in multiple clinical development projects to collect and analyze objective and ongoing patient physiological data. It is hoped that analysis of previously unobtainable, real-time vital data will visualize the comprehensive outcome of drug treatments developed by us. In addition, through the development of dBM, we aim to understand diseases more deeply and provide new values for the prevention of diseases, very early diagnosis, and improvement of Quality of Life (QOL) after treatment.

Digital biomarkers (dBM) initiatives

Establishment of an assessment method for pain in endometriosis

  • We use wearable devices and the AI platform co-developed with Biofourmis to validate the possibility of assessing pain objectively and continuously.
  • The AI platform of Biofourmis includes a dashboard that a physician can access remotely, a wearable device worn by a patient, and an app. It has functions to obtain, collect, and analyze patients’ vital data. Further, it records symptoms, and quantifies pain using collected data, and includes gamification to encourage patients to continue using the device.
  • Device: E4®

News release “Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology” (July 22, 2020) [PDF 196KB]

Our initiative on hemophilia

  • We evaluated the association between physical activity and hemorrhagic events reported by patients, as well as biological data collected during the activity by a wearable activity meter.
  • Device: ActiGraph Insightwatch
  • ePRO: Welby’s exclusive app

CAREERS

Chugai is looking for talent to help us harness digital technology to become a leading innovator in the healthcare industry.

  • Like
  • Tweet
  • LINE it!
  • E-mail

Digital Transformation "CHUGAI DIGITAL"

Back to top